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Abstract The adenosine A2B receptor is the least well
characterized of the four adenosine subtypes due to the lack
of potent and selective agonists and antagonists. Despite the
widespread distribution of A2B receptor mRNA, little
information is available with regard to their function. The
characterization of A2B receptors, through radioligand
binding studies, has been performed, until now, by
using low-affinity and non-selective antagonists like
1,3-dipropyl-8-cyclopentylxanthine ([
3H]DPCPX),(4-(2-
[7-amino-2-(2-furyl)-[1,2,4]triazolo-[2,3-a][1,3,5]triazin-5-
ylamino]ethyl)-phenol ([
3H]ZM 241385) and 3-(3,
4-aminobenzyl)-8-(4-oxyacetate)phenyl-1-propyl-xanthine
([
125I]ABOPX). Recently, high-affinity radioligands for
A2B receptors, [N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetra-
hydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy]
acetamide ([
3H]MRS 1754), N-(2-(2-Phenyl-6-[4-(2,2,3,3-
tetratritrio-3-phenylpropyl)-piperazine-1-carbonyl]-7H-pyr-
rolo[2,3-d]pyrimidin-4-ylamino)-ethyl)-acetamide ([
3H]
OSIP339391) and N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-
dipropyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-
methyl-1H-pyrazol-3-yloxy]-acetamide] ([
3H]MRE
2029F20), have been introduced. This minireview offers an
overview of these recently developed radioligands and the
most important applications of drugs towards A2B receptors.
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Abbreviations
ABOPX 3-(3,4-aminobenzyl)-8-(4-oxyacetate)phe-
nyl-1-propyl-xanthine
DPCPX 1,3-dipropyl-8-cyclopentyl-xanthine
IB-MECA N
6-(3-iodo-benzyl) adenosine-50-N-meth-
yluronamide
IPDX 3-isobutyl-8-pyrrolidinoxanthine
MRE
3008F20
5-N-(4-methoxyphenyl-carbamoyl)amino-
8-prpyl-2(2furyl)-pyrazolo-[4,3e]-1,2,4-tri-
azolo [1,5-c]pyrimidine
MRE 2029-
F20
N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-
dipropyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-
purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-
acetamide]
MRS 1754 [N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahy-
dro-2,6-dioxo-1,3-dipropyl-1H-purin-8-
yl)-phenoxy]acetamide
NECA 50-N-ethylcarboxamidoadenosine
OSIP339391 N-(2-(2-Phenyl-6-[4-(2,2,3,3-tetratritrio-3-
phenylpropyl)-piperazine-1-carbonyl]-7H-
pyrrolo[2,3-d]pyrimidin-4-ylamino)-ethyl)-
acetamide
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e-mail: bpa@dns.unife.itSCH 58261 7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-
e]-1,2,4-triazolo[1,5-c]-pyrimidine
hA2BHEK 293
cells
Human embryonic kidney-293 cells trans-
fected with human adenosine A2B receptor
PLC Phospholipase C
ZM 241385 (4-(2-[7-amino-2-(2-furyl)-[1,2,4]triazolo-
[2,3-a][1,3,5]triazin-5-ylamino] ethyl)-
phenol
Introduction
Adenosine, an ubiquitous nucleoside released from meta-
bolically active or stressed cells, is known to act as an
important regulatory molecule through activation of cell
surface receptors named A1,A 2A,A 2B and A3, all of which
belong to the G protein-coupled superfamily of receptors [1].
In particular A1 and A3 inhibit, through Gi proteins,
adenylyl cyclase activity, whereas A2A and A2B stimulate,
via Gs proteins, this enzyme. Collectively, these receptors
are widespread on virtually every organ and tissue and
represent promising drug targets for the pharmacological
intervention in many pathophysiological conditions that are
believed to be associated with changes of adenosine levels
such as asthma, neurodegenerative disorders, chronic in-
flammatory diseases and cancer [2, 3]. It has been suggested
that adenosine receptors act as “sensors” and that extracel-
lular adenosine acts as a “reporter” of metabolic changes in
the local tissue environment [4, 5]. Therefore, under normal
conditions adenosine, which is continuously produced
intracellularly and extracellularly and maintained at low
intracellular levels (about 100 nM) by adenosine kinase and
adenosine deaminase, interacts with the high-affinity A1 and
A2A receptor subtypes. In hypoxic, ischaemic or inflamed
conditions the intracellular production of adenosine is
increased to very high micromolar concentrations and
transported across cell membranes by specific agents finally
leading to the stepwise activation of all adenosine receptors,
including the low-affinity A2B and A3 subtypes [6].
Whilst for A1,A 2A and A3 adenosine subtypes good
agonists and antagonists have been synthesized allowing a
plethora of binding and functional studies, no high-affinity
analogues have been identified for the A2B receptors until a
couple of years ago, and neither high-affinity nor selective
antagonists had been introduced until 2001 [3, 7, 8].
Therefore studies concerning A2B receptors rely on mRNA
distribution, cloning and functional assays performed with
not very selective molecules [9]. However considering the
potential therapeutic applications of A2B ligands, many
efforts have been made in the last few years to search for
potent and selective antagonists versus this receptor subtype
[10] and the recent discovery of novel radiolabelled A2B
antagonists will be useful to the scientific community for
the exploration and characterization of the pathophysiolog-
ical role of A2B receptors.
A2B adenosine receptors
A2B receptors were distinguished from A2A in 1983 [11]
due to the high and low affinity of adenosine in the
stimulation of cAMP levels in rat striatum and were cloned
for the first time in 1992 from human hippocampus [12]
and rat brain [13, 14] and subsequently from mouse bone
marrow-derived mast cells [15]. The distribution of A2B
receptors has been detected on practically every cell in
different species and relies on the reverse transcription
polymerase chain reaction technique. A2B messenger RNA
has been found at low levels in all rat brain regions
evaluated, aorta, stomach, testis, skeletal muscle, jejunum,
kidney, heart, skin, spleen and liver whilst high levels have
been detected in the proximal colon [6]. A2B are coupled to
different signalling pathways such as stimulation of
adenylate cyclase through Gs proteins and accumulation
of intracellular calcium. This pathway is related to different
mechanisms such as potentiation of a P-type calcium
current in hippocampal neurons [16], activation of a
calcium channel, Gs protein-coupled, in human erythroleu-
kemia cells [17] or involvement of phospholipase C in
HMC1 cells [18]. More recently, it has also been suggested
that they are involved in activation of extracellular
regulated kinases 1/2 (ERK1/2) at physiologically normal
concentrations [19, 20]. Functional studies have suggested
the presence of A2B receptors in airway smooth muscle,
fibroblasts, vasculature, mast cells, macrophages, endothe-
lium, haematopoietic cells and intestinal epithelial cells. In
particular, they have been reported to be involved in
stimulation of cell proliferation, differentiation and migra-
tion of retinal endothelial cells, where A2B antagonists may
offer a way to inhibit retinal angiogenesis and provide a
novel therapeutic approach for treatment of diseases asso-
ciated with aberrant neovascularization, such as diabetic
retinopathy [21, 22]. In macrophages it has been reported
that their up-regulation induced by interferon gamma
(IFN-γ) would lead to the cAMP-mediated down-regula-
tion of MHC class II molecules and other macrophage
activities. This may constitute an important mechanism of
cell deactivation at the inflammatory foci [23]. In human
mast cells 50-N-ethyl-carboxamidoadenosine (NECA) in-
duced interleukin-8 secretion through the involvement of
p38 mitogen-activated protein kinase and extracellular
signal-regulated protein kinase kinase and this effect was
blocked by 3-isobutyl-8-pyrrolidinoxanthine (IPDX) sug-
gesting a basis for the development of new antiasthmatic
drugs [24–26]. The recent discovery that A2B receptors are
also functionally active on human airway smooth muscle
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on lung fibroblasts where they promote differentiation to a
myofibroblast phenotype [28] supports the view that this
subtype may be involved in airway wall remodelling and in
asthma [29]. Interestingly a role of A2B receptors has also
been observed in the analgesic effects of caffeine in an
acute animal model of nociception, suggesting that specific
A2B antagonists might be valuable adjuvant drugs for
opioid analgesia with minimal side effects [30]. The high
expression of A2B receptors in different parts of the
intestinal tract raised great interest in defining their
function. It has been suggested that they play a role in
epithelial secretion with potential relevance to diarrhoeal
processes [31]. Moreover A2B receptors are involved in
coronary flow regulation [32], stimulation of proangiogenic
factors [33–35] and they have been proposed as targets to
control cell growth and proliferation in a human breast
cancer cell line [36]. All together these effects suggest a
possible role of the A2B subtype in the modulation of
inflammatory processes involved in asthma, tumour
growth, tissue injury, ischaemia and pain [37, 38]. Target-
ing of the A2B receptor protein to specific cells or tissues is
crucial in order to understand their role in pathophysiolog-
ical conditions. Unfortunately, the lack of selective agonists
and antagonists has hampered the pharmacological charac-
terization of this receptor system. Only recently Ijzerman’s
group developed new, high-potency A2B agonists with an
improved selectivity profile compared to the reference
agonist NECA, and the discovery of the first A2B partial
agonist that appears very promising for future functional
studies [39]. The characterization of A2B receptors, there-
fore, often was based on the lack of effectiveness of
compounds that are potent and selective agonists of other
receptor subtypes. The agonist CGS 21680, for example,
has been useful in differentiating between A2A and A2B
receptors [40]. However, pharmacological characterization
of receptors based on apparent agonist potencies is far from
ideal, because it depends not only on agonist binding to the
receptor but also on multiple processes involved in signal
transduction. Recently, based on functional assays using
novel A2B selective antagonists, significant progress has
been made in the understanding of the molecular pharma-
cology and physiology of A2B adenosine receptors and
novel progress in this field is supposed to be increased by
the introduction of the tritiated radiolabelled form of some
new A2B antagonists named [
3H]MRS 1754, [
3H]
OSIP339391 and [
3H]MRE 2029-F20 [41–43].
Novel antagonist radioligands to A2B adenosine subtype
The characterization of A2B receptors, through radioligand
binding studies, has been performed, until now, by using
low-affinity and non-selective antagonists like [
3H]DPCPX,
[
3H]ZM 241385 and [
125I]ABOPX, which, as a conse-
quence of their low affinity, display a rapid dissociation rate
from the receptor [44]. In addition, since these ligands are
non-selective their utility in native systems is hampered as
many tissues and cell lines express several adenosine
subtypes.
Xanthines, including the natural derivatives theophylline
and caffeine, are the natural non-selective antagonists of
adenosine and they are able to bind to all four adenosine
receptor subtypes A1,A 2A,A 2B and A3 [6]. Therefore the
xanthine core has been maintained and modified in order to
develop new A2B drugs. This approach led to the discovery
of new molecules introduced as high-affinity radioligands
for A2B receptors named [
3H]MRS 1754, [
3H]OSIP339391
and [
3H]MRE 2029-F20 [41–43].
MRS1754, which belongs to a series of amides derived
from the 8-phenyl xanthine molecules [45], was the first
antagonist proposed in radiolabelled form for the labelling
of A2B receptors [41]. MRS1754 was shown to be a potent
and selective antagonist. Radioligand binding studies
showed that it binds to recombinant A2B receptors in
membranes of stably transfected HEK 293 cells. Specific
binding was saturable, competitive, and followed a one-site
model, with a KD value of 1.13 nM and a Bmax value of
10.9 pmol/mg protein. Specific binding of [
3H]MRS 1754,
at the KD value, was >70% of total binding. The affinity
calculated from association and dissociation binding con-
stants was 1.22 nM. Binding to membranes expressing rat
and human A1 and A3 adenosine receptors was not
significant, and binding in membranes of HEK 293 cells
expressing human A2A receptors was of low affinity
(KD > 50 nM). The pharmacological profile in competition
experiments with [
3H]MRS 1754 was consistent with the
structure-activity relationship for agonists and antagonists
at A2B receptors. In spite of the high affinity and selectivity,
this radioligand has not been used in cells and tissues
endogenously expressing A2B receptors.
Some years later a pyrrolopyrimidine compound [
3H]
OSIP339391 was introduced as a high-affinity and selective
radioligand to A2B receptors [42]. OSIP339391 had a
selectivity of greater than 70-fold for A2B receptors over
other human adenosine receptor subtypes. Using mem-
branes from HEK 293 cells expressing the human recom-
binant A2B receptor, [
3H]OSIP339391 was characterized in
kinetic, saturation and competition binding experiments.
From the association and dissociation rate studies, the
affinity was 0.41 nM and in close agreement with that
found in saturation binding experiments (0.17 nM). In
competition binding studies of [
3H]OSIP339391, the
affinity of a range of agonists and antagonists was con-
sistent with previously reported data. However, also in this
case, its suitability to label endogenous A2B receptors
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cells or tissues.
Our research group has identified a series of 8-pyrazole
xanthine derivatives as potent and selective human A2B
adenosine antagonists [46], and a radiolabelled form of one
compound of this series, [
3H]MRE 2029-F20 [47], was used
as new pharmacological tool to describe the comparison
between human recombinant A2B receptors stablytransfected
in HEK 293 cells and endogenous receptors present in human
neutrophils and lymphocytes [43]. [
3H]MRE 2029-F20
showed high affinity and selectivity for hA2B versus hA1,
hA2A and hA3 subtypes. The selectivity of MRE 2029-F20
for the human A2B over A1,A 2A and A3 receptors was
evaluated in radioligand binding assays by using [
3H]
DPCPX, [
3H]ZM 241385 and [
3H]MRE 3008-F20, respec-
tively. MRE 2029-F20 displays low affinity for the human
A1 receptor (Ki = 245 ± 31 nM) and no significant affinity
for the human A2A and A3 subtypes (Ki >1,000 nM). This
indicates that MRE 2029-F20 is 88- and more than 300-fold
selective for the A2B over A1,A 2A and A3 subtypes,
respectively, which means a range of selectivity similar to
[
3H]MRS 1754 (selectivity of 210-, 260- and 290-fold for
A2B over A1,A 2A and A3 subtypes, respectively) and slightly
better than [
3H]OSIP339391 (selectivity of 70-fold for A2B
over A1,A 2A and A3 subtypes, respectively).
[
3H]MRE 2029-F20 bound specifically to the hA2B re-
ceptor stably transfected in human embryonic kidney (HEK)
293 cells with KD of 2.8 nM and Bmax of 450 fmol/mg of
protein. Saturation experiments of [
3H]MRE 2029-F20
binding in human neutrophils and lymphocytes detected a
single high-affinity binding site with KD values of 2.4 and
2.7 nM, respectively, and Bmax values of 79 and 54 fmol/
mg of protein, respectively, in agreement with real-time
reverse transcription polymerase chain reaction studies
showing the presence of A2B mRNA. The rank order of
potency of typical adenosine ligands with recombinant
hA2B receptors was consistent with that typically found for
interactions with the A2B subtype and was also similar in
peripheral blood cells. NECA stimulated cAMP accumula-
tion in both hA2BHEK 293 and native cells, whereas
phospholipase C activation was observed in recombinant
receptors and endogenous subtypes expressed in neutro-
phils but not in lymphocytes. MRE 2029-F20 was revealed
to be a potent antagonist in counteracting the agonist effect
in both signal transduction pathways. In conclusion, [
3H]
MRE 2029-F20 was revealed to be a selective and high-
affinity radioligand for the hA2B adenosine subtype and
may be used to quantify A2B endogenous receptors such as
those present in neutrophils and lymphocytes that represent
inflammatory cells potentially involved in the exacerbation
of asthma and other inflammatory processes in which A2B
receptors are thought to be involved [29]. This was the first
paper reporting both binding and functional studies in
recombinant and native receptors. [
3H]MRE 2029-F20 has
been used also to evaluate the effects of novel and
recognised compounds at human recombinant A2B adeno-
sine receptors expressed in Chinese hamster ovary, in HEK
293 and at endogenous A2B receptors in human mast cells
(HMC-1). Saturation binding experiments performed using
[
3H]MRE 2029-F20 revealed a single class of binding sites
in hA2BCHO, hA2BHEK 293 and HMC-1 cells with KD of
1.65, 2.83, 2.62 nM and Bmax of 36, 475 and 128 fmol/mg
protein, respectively. Moreover, the compounds tested were
able to decrease NECA-stimulated and also forskolin-
stimulated cAMP production, revealing them to be novel
antagonists with an inverse agonist activity in recombinant
and native human A2B receptors [48].
Conclusions
In recent years remarkable attention has been paid to A2B
receptors due to their supposed role in important patholog-
ical states such as asthma, diarrhoeal processes, diabetic
retinopathy, vasodilation, neoangiogenesis and nociception.
For many years their study has been strongly limited by the
lack of good and selective pharmacological probes and
many efforts have been focused by chemists and biologists
on the synthesis and testing of new selective ligands. The
data presented in this review clearly underline the signif-
icant progress made in the field of A2B receptor antagonists.
Novel high-affinity and selective antagonist radioligands
have been recently synthesized that will allow in the future
the characterization of this adenosine subtype in endoge-
nous systems (Table 1).
Table 1 Binding characteristics of the recently developed antagonist radioligands to A2B recombinant receptors. Specific binding is expressed at
the KD value of each radioligand.
Radioligand KD (nM) Bmax (fmol/mg of protein) Specific binding (%) hA1 Ki (nM) hA2A Ki (nM) hA3 Ki (nM)
[
3H]-MRS 1754
a 1.13 ± 0.12 10,900 ± 600 70 403 ± 194 503 ± 10.8 570 ± 184
[
3H]-OSIP339391
b 0.17 ± 0.05 20,102 ± 1,503 80 37 ± 7 328 ± 75 450 ± 55
[
3H]-MRE 2029-F20
c 2.8 ± 0.2 450 ± 42 70 248 ± 30 >1,000 >1,000
aSee ref. [41]
bSee ref. [42]
cSee ref. [43]
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